Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Recommended combination of Shire and AbbVie

View the press release

Excellence in ADHD Patient Group Awards

Submit your nomination today!

We’re recognizing outstanding contributions by patient organizations based outside of the USA and the UK to support people living with ADHD.

View the Press Release

Read More

Shire completes acquisition of Lumena

Lumena is an excellent strategic fit that will enhance Shire’s commitment to patients with life-altering conditions and the Company’s rare disease portfolio and GI business unit.

View the Press Release


2013 Annual Report

We are focused on growing Shire by developing and marketing innovative specialty medicines that address significant unmet patient needs.

View our Annual Report

Download our Annual Report 2013 (PDF)

Shire's Stance 

Shire opposes the misuse, abuse, and diversion of prescription ADHD medicines.

Read more here


Shire launches new Clinical Trials website serves as the source for Shire-sponsored clinical trials, as well as a resource for education and awareness about clinical research. It also provides increased transparency into Shire’s data sharing practices.


Share price

23 Jul 2014
At least 15 minutes delayed

Our products

Shire has a wide range of products on the market and will ensure that it can make more products available in the future.


Our responsibility

What Responsibility Means

What Responsibility means to Shire. Read more here.

Our stance on ADHD

Shire Opposes Misuse, Abuse and
Diversion of Prescription ADHD
Medicines. Read more here.

Shire collaborates with Sedex

Read about our efforts in qualifying our suppliers to ensure they are doing business in a manner that reflects our own values.